Shindel Alan W, Mann Margaret W, Lev Ronan Y, Sengelmann Roberta, Petersen Jeffrey, Hruza George J, Brandes Steven B
Division of Urology, Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri 63110, USA.
J Urol. 2007 Nov;178(5):1980-5. doi: 10.1016/j.juro.2007.07.039. Epub 2007 Sep 17.
Mohs micrographic surgery is efficacious for the primary treatment and local recurrence control of nongenital and cutaneous squamous and basal cell cancers. The efficacy of this procedure for squamous cell carcinoma of the penis was reviewed.
We retrospectively reviewed the charts of all patients treated with Mohs micrographic surgery for penile cancer at our institution from 1988 to 2006.
We identified 33 patients who underwent a total of 41 Mohs procedures. Average +/- SD lesion size was 509 +/- 699 mm(2). An average of 2.6 +/- 1.4 stages were done using Mohs micrographic surgery. Five procedures were terminated with positive margins, including 3 due to urethral involvement and 2 due to defect size. Of the tumors 26 were stage Tis, 4 were T1, 7 were T2 and 4 were T3. A total of 13 defects were reconstructed by primary repair or granulation, 4 were reconstructed by skin grafts and 25 were reconstructed by tissue flaps and urethroplasty. Followup data were available on 25 patients at a mean of 58 +/- 63 months. Eight patients (32%) had recurrence, which was managed by repeat Mohs micrographic surgery in 7 and by penectomy in 1. There were 2 cases of tumor progression, including 1 from T1 to T3 disease (meatal involvement) and 1 from T1 to inguinal lymph node involvement. Two patients died, of whom 1 had no evidence of penile cancer and 1 had metastatic disease.
Mohs micrographic surgery for low stage penile cancer results in a relatively high local recurrence rate. However, with repeat procedures and vigilant followup cancer specific and overall survival rates are excellent and progression rates are low.
莫氏显微外科手术对非生殖器皮肤鳞状细胞癌和基底细胞癌的初始治疗及局部复发控制有效。本研究回顾了该手术治疗阴茎鳞状细胞癌的疗效。
我们回顾性分析了1988年至2006年在我院接受莫氏显微外科手术治疗阴茎癌的所有患者的病历。
我们确定了33例患者,共进行了41次莫氏手术。病变平均大小±标准差为509±699 mm²。平均进行了2.6±1.4个阶段的莫氏显微外科手术。5次手术切缘阳性终止,其中3次因尿道受累,2次因缺损大小。肿瘤分期为Tis期26例,T1期4例,T2期7例,T3期4例。共13处缺损通过一期修复或肉芽组织修复,4处通过植皮修复,25处通过组织瓣和尿道成形术修复。25例患者有随访数据,平均随访时间为58±63个月。8例患者(32%)复发,其中7例通过再次莫氏显微外科手术处理,1例通过阴茎切除术处理。有2例肿瘤进展,1例从T1期进展为T3期(尿道口受累),1例从T1期进展为腹股沟淋巴结受累。2例患者死亡,其中1例无阴茎癌证据,1例有转移性疾病。
莫氏显微外科手术治疗低分期阴茎癌局部复发率相对较高。然而,通过重复手术和密切随访,癌症特异性生存率和总生存率良好,进展率较低。